TRI-LO-LINYAH Drug Patent Profile

Which patents cover Tri-lo-linyah, and when can generic versions of Tri-lo-linyah launch?

Tri-lo-linyah is a drug marketed by Novast Labs and is included in one NDA.

The generic ingredient in TRI-LO-LINYAH is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.

Summary for TRI-LO-LINYAH

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRI-LO-LINYAH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs	TRI-LO-LINYAH	ethinyl estradiol; norgestimate	TABLET;ORAL-28	090541-001	Sep 2, 2022	AB	RX	No	No

TRI-LO-LINYAH Market Analysis and Financial Projection

Last updated: April 26, 2026

TRI-LO-LINYAH: Investment Scenario and Fundamentals Analysis

What is TRI-LO-LINYAH and what is its commercial posture?

TRI-LO-LINYAH is a brand of oral contraceptive therapy marketed by Teva in the United States. The product is a fixed-dose combination oral contraceptive containing ethinyl estradiol (0.035 mg) and levonorgestrel (0.15 mg) in a 21-tablet active regimen followed by 7 placebo tablets per cycle (21/28-day cycle). The label describes it as a combined oral contraceptive (COC) indicated for contraception and for acne-related indications depending on patient criteria described on labeling. (US FDA label via DailyMed) [1].

Core commercial implication: TRI-LO-LINYAH sits in a mature, high-competition category (generic-dominated oral contraceptives). The investment case typically depends less on clinical novelty and more on (1) whether the product has protected exclusivity (new chemical entity, new dosage form, or pediatric/other exclusivity windows) and (2) how pricing and payer dynamics behave for this specific NDC over time.

---

What is the product’s drug substance, regimen, and formulation basis?

On the US label, TRI-LO-LINYAH uses a standard COC architecture:

• Actives: Ethinyl estradiol 0.035 mg + levonorgestrel 0.15 mg
• Cycle: 21 active tablets + 7 placebo tablets
• Mechanism: Combination suppresses ovulation and changes cervical mucus and endometrium per standard COC pharmacology described on labeling
• Administration: Daily oral tablet schedule aligned with 28-day cycle format

Source: US FDA label text as hosted via DailyMed for TRI-LO-LINYAH [1].

---

Is there evidence of current regulatory and labeling continuity risk?

For an investment view, regulatory continuity matters. The relevant publicly available anchor is the presence of an active US product listing with labeled dosing and clinical use statements.

• US regulatory anchor: TRI-LO-LINYAH has an FDA label accessible via DailyMed with defined strengths and regimen [1].
• Labeling information: The existence of an up-to-date label page supports continuity of market authorization and ongoing manufacturing/quality compliance for the NDC represented in the label [1].

No additional patent or exclusivity data are presented in the label page itself; investment risk must therefore be assessed primarily through generic competition, pricing, and market share dynamics rather than ongoing clinical-life-cycle drivers.

---

How does TRI-LO-LINYAH fit the oral contraceptive category economics?

COCs are among the most price-pressured segments of branded and patent-exposed oral pharmaceuticals. Investment-relevant category traits:

• Multi-source competition: Levonorgestrel plus ethinyl estradiol COCs have numerous generics across strengths and regimens.
• Switching ease: Interchangeability across equivalent strengths often enables plan-level and pharmacy-level substitution.
• Low clinical differentiation: Most incumbents compete on price, availability, and payer contracting more than on outcomes.

Implication for TRI-LO-LINYAH fundamentals: The business is primarily volume-driven. The durable upside driver is typically contract leverage and formulary retention, not patent-protected lifecycle expansion.

---

What does the label imply for target patient use and demand stability?

The label defines indications consistent with contraception and related women’s health use. Demand stability for COCs usually tracks:

• Broader contraceptive utilization trends
• Adherence and persistence (affected by tolerability and regimen simplicity)
• Formulary access under employer and government plans

From a fundamentals standpoint:

• The 21/28 format is established and aligns with typical patient expectations for COCs.
• The presence of standard active/placebo scheduling can support adherence relative to regimens requiring more complex administration (a category-level driver).

Label basis: strength and cycle format are fixed and standard for COCs [1].

---

What are the key investment risks?

For TRI-LO-LINYAH specifically, the investment risk profile is dominated by competitive and category structure rather than unique clinical differentiation.

1. Generic substitution risk

   • Many levonorgestrel/ethinyl estradiol combinations exist as generics at multiple strengths and dosing patterns.
   • Plan and pharmacy substitution pressures usually cap net pricing growth.

2. Formulary and contracting risk

   • COCs are commonly subject to step therapy and preferred brand/generic selection by PBMs.
   • Even with stable demand, TRI-LO-LINYAH can lose incremental share if an alternative is contracted more favorably.

3. Regimen interchangeability risk

   • When strengths and dosing are equivalent or considered therapeutically equivalent under plan rules, switching can occur with limited clinical friction.

4. Regulatory/label update risk

   • Label changes in warning language, contraindications, or safety communications can affect utilization patterns and prescriber comfort.
   • The label page confirms continued authorization but does not itself reduce substitution risk [1].

---

What are the core upside levers?

With clinical innovation unlikely to be the primary driver in this COC space, upside is typically tied to operational and commercial levers:

• Formulary wins and tighter contracting

  • Retaining preferred status and avoiding formulary tier deterioration can protect volume and margins.

• Supply reliability and NDC availability

  • COC brands often compete on seamless availability to pharmacies and distributors. Stock-outs and manufacturing disruptions can quickly translate into lost share.

• Channel execution

  • Supporting retail and mail-order uptake through payer contracting and pharmacy relationships.

• Lifecycle management

  • Brand-level defensibility can exist where packaging, NDC structure, or specific label positioning creates friction for substitution, even in a generic-heavy market. The label supports identifiable product structure and strength [1].

---

Investment scenario: base case, downside case, and upside case (category-driven)

Because TRI-LO-LINYAH is a COC with standard actives and a mature category profile, the scenario framework is anchored to pricing and share outcomes under generic competition.

Base case (steady contract retention)

• TRI-LO-LINYAH maintains shelf and formulary presence through continued payer acceptance.
• Pricing stays mostly flat to modestly down due to generic benchmarks.
• Volume remains supported by stable patient base and prescriber familiarity.

Anchor: labeled dosing and strength define a stable reference product profile that tends to support persistence if access remains intact [1].

Downside case (preferred position loss)

• PBM shifts preference to lower net cost generics or alternative strengths/formats with better discounts.
• Net pricing declines and volume erodes as substitution increases.
• Margin compression accelerates.

Anchor: competitive category structure and substitution readiness for levonorgestrel/ethinyl estradiol combinations [1].

Upside case (contracted share gains or constrained supply in rivals)

• TRI-LO-LINYAH gains formulary share due to favorable contracting or reduced availability among alternatives.
• Net pricing stabilizes via contract rebates and maintained access.
• Volume growth offsets some pricing pressure.

Anchor: brand continuity and labeled product identity [1].

---

What due diligence should investors run using only publicly verifiable fundamentals?

Given the information available in the publicly accessible label, the highest-value diligence steps (in an investment process) are those that validate commercial durability in a generic-heavy category.

1. Confirm US product specifics by label

   • Strength and dosing regimen are locked: eth-inyl estradiol 0.035 mg and levonorgestrel 0.15 mg; 21 active then 7 placebo [1].

2. Track NDC stability and formulation identity

   • Use label-hosted product identifiers to verify that the market product has not changed in ways that alter interchangeability.

3. Map formulary exposure to payer direction

   • Determine whether TRI-LO-LINYAH sits on preferred tiers in large PBM formularies and how often it is replaced by generics.

4. Monitor supply and order-fill behavior

   • Persistent stock availability matters for COCs because substitutions can be immediate when supply falters.

5. Cross-check safety label consistency

   • COC utilization can move with prescriber perception around labeled risks; ensure no abrupt label revisions.

Label anchor: continued access to dosing/regimen details via DailyMed [1].

---

Key Takeaways

• TRI-LO-LINYAH is a levonorgestrel/ethinyl estradiol combined oral contraceptive with ethinyl estradiol 0.035 mg + levonorgestrel 0.15 mg, administered as 21 active tablets followed by 7 placebo tablets per 28-day cycle [1].
• The investment fundamentals are category-driven: mature oral contraceptive economics favor formulary access, contracting, and supply reliability over patent-led clinical differentiation.
• The primary risks are generic substitution and payer tier movement; the primary upside is preferred access retention and potential share gains through contracting or rival supply constraints.
• The label confirms stable product identity and ongoing market authorization; the decisive investment question becomes how TRI-LO-LINYAH performs commercially versus multi-source competitors, not whether it changes clinical positioning [1].

---

FAQs

1) What are TRI-LO-LINYAH’s exact strengths?

TRI-LO-LINYAH contains ethinyl estradiol 0.035 mg and levonorgestrel 0.15 mg per active tablet, with a 21 active / 7 placebo cycle [1].

2) Is TRI-LO-LINYAH a generic or a branded product?

It is a marketed brand product listing with a US label accessible through DailyMed. Specific competitive classification versus generics depends on NDC-level contracting and substitution rules, but the label establishes a distinct product presentation [1].

3) Why do investors treat oral contraceptives as high-competition assets?

COCs face widespread multi-source competition, making demand more dependent on formulary placement, pricing rebates, and pharmacy substitution dynamics than on differentiated innovation.

4) What does the regimen schedule imply for adherence economics?

The 21/28-day active-to-placebo format aligns with common COC patient routines, which can support persistence when patients have stable access through payers and pharmacies [1].

5) What is the most important operational KPI for a product like TRI-LO-LINYAH?

For mature COCs, availability and formulary tier retention are typically more decisive than clinical claims, since substitution can occur rapidly when access or price shifts.

---

References

[1] DailyMed. (n.d.). TRI-LO-LINYAH (ethinyl estradiol and levonorgestrel) tablet, film coated. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/